Formulation: A solid
Formal Name: 3-[3,5-dimethyl-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-1-[4-(phenylmethyl)-1-piperidinyl]-1-propanone
Purity: ≥98%
Formula Markup: C26H31N7O
Formula Weight: 457,6
Shelf life (days): 1460
CAS Number: 1358099-18-9
Notes: C25-140 is an inhibitor of the protein-protein interaction between the E3 ligase TNF receptor-associated factor 6 (TRAF6) and ubiquitin-conjugating enzyme E2 N (Ubc13; IC50 = 2.6 µM).{72163} It selectively inhibits the TRAF6-Ubc13 interaction over the interactions between Ubc13-OTUB1 and Ubc13-Uev1a. C25-140 (30 µM) also selectively inhibits TRAF6-dependent ubiquitination over a panel of various E3 ligase/E2 enzymes, but does inhibit cellular inhibitor of apoptosis 1 (cIAP1) and E1/E2 enzymes in cell-free assays. It reduces IL-1β-induced activation of NF-κB in mouse embryonic fibroblasts (MEFs) when used at a concentration of 50 µM. Topical application of C25-140 (~1.5 mg/kg twice per day) reduces scaling and erythema in a mouse model of psoriasis induced by the TLR7 agonist imiquimod (Item No. 14956). It decreases disease severity in a mouse model of collagen-induced arthritis when administered at doses ranging from 6 to 14 mg/kg twice per day. C25-140 (5 mg/kg) also reduces alveolar septal thickening, pulmonary edema, and inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF) in a mouse model of lung injury induced by mechanical ventilation with high tidal volumes.{72164}
English
Deutsch
